跳至主要内容
临床试验/NCT03697148
NCT03697148进行中(未招募)不适用

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

ECOG-ACRIN Cancer Research Group69 个研究点 分布在 1 个国家目标入组 852 人开始时间: 2019年2月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
852
试验地点
69
主要终点
Risk prediction model

研究概览

简要总结

This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.

详细描述

PRIMARY OBJECTIVES:

I. To estimate the diagnostic performance as quantified by the area under the ROC curve to detect aggressive prostate cancer.

II. To develop a risk prediction model by incorporating overall PI-RADS, PSA, Gleason score and clinical stage to predict the presence of aggressive prostate cancer.

SECONDARY OBJECTIVES:

I. To evaluate the diagnostic performance of the individual PI-RADS score of each MRI parameter (T2W, DWI and DCE), as determined by local imaging review.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Recently diagnosed with prostate cancer for whom definitive surgical treatment is indicated

排除标准

  • Not suitable to undergo MRI or receive gadolinium-based contrast agent (severe, untreatable claustrophobia; MRI-incompatible metallic objects or implanted medical devices; renal failure; weight greater than allowable by scanner per institutional standard practice)
  • Prior surgical and/or non-surgical treatment for prostate cancer
  • Prior hip replacement or other major pelvic surgery

研究组 & 干预措施

Diagnostic (mpMRI)

Experimental

Patients undergo mpMRI within 3 months prior to schedule surgery.

干预措施: Multiparametric Magnetic Resonance Imaging (Diagnostic Test)

结局指标

主要结局

Risk prediction model

时间窗: Up to 2 years

To estimate the predictive performance of a model for predicting clinically significant prostate cancer on the basis of the overall PI-RADS, PSA, Gleason score and clinical stage.

Diagnostic performance of overall prostate imaging reporting and data system (PI-RADS) score

时间窗: Up to 2 years

Will estimate the diagnostic performance as quantified by the area under the ROC curve.

次要结局

  • Diagnostic performance of the individual prostate imaging reporting and data system (PI-RADS) score(Up to 2 years)

研究者

发起方
ECOG-ACRIN Cancer Research Group
申办方类型
Network
责任方
Sponsor

研究点 (69)

Loading locations...

相似试验

Multiparametric MRI in Evaluating Cancer Stage and... | 临床试验